Initially, the patient must schedule an interview with one of the doctors on our clinical staff.
On the day of the interview, the patient must bring with him the results of any laboratory tests, including recent complete blood count, creatinine dosage, PSA, in addition to a prior PSMA PET/CT test and exam request.
This therapy is not recommended for patients who have undergone recent myelosuppressive therapy, and should be performed at least 6 weeks after the last cycle of chemotherapy
PREPARATION:
- Fasting is not necessary.
- Prior abundant hydration (water, juice, soft drinks) is recommended.
HOW IS THERAPY PERFORMED?
After the registration form is filled out at the reception desk, the patient will be sent to the bedrest room.
A peripheral vein will be punctured and maintained with saline. After confirming that the puncture is adequate, the drug will be injected slowly and the access will be maintained with saline solution for hydration.
At medical discretion, corticosteroids, antiemetics and diuretics may be used.
Note: some services use ice packs that are applied to the topography of the salivary glands before PSMA infusion, to promote vasoconstriction and protection of these structures.
GUIDELINES AFTER THERAPY:
The patient will be followed by the referring physician and nuclear medicine physician.
The most frequently observed adverse reactions were fatigue, dry mouth, myelosuppression and, more rarely, renal alterations. That is why weekly clinical follow-up is important.
The patient will be instructed to return to the clinic 24 to 48 hours after the injection of 177Lu-PSMA, for image acquisition (post-dose WBS).
Abundant hydration and rest for 24 hours after therapy are recommended.
OE 061 – Version: 02/2024
Made by: DIMEN Technical Team
